Immune Design. Revenue Growth Rates (IMDZ), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immune Design Corp.  (IMDZ)
 

IMDZ's Revenue Growth by Quarter and Year

Immune Design.'s Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMDZ Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
4th Quarter December 0.48
3rd Quarter September 0.46
2nd Quarter June 0.76
1st Quarter March 0.50
FY 2.20

IMDZs Annual Revenue
Immune Design.'s Revenue in the fiscal year 2018 $ 2.20 millions
Immune Design.'s Revenue in the fiscal year 2017 $ 7.20 millions
Immune Design.'s Revenue in the fiscal year 2016 $ 13.26 millions
Immune Design.'s Revenue in the fiscal year 2015 $ 9.51 millions
Immune Design.'s Revenue in the fiscal year 2014 $ 6.43 millions




IMDZ Revenue fourth quarter 2018 Y/Y Growth Comment
Immune Design Corp. reported decrease in Revenue in the fourth quarter 2018 by -2.86% to $ 0.48 millions, from the same quarter in 2017.
The decrease in the fourth quarter 2018 Immune Design Corp.'s Revenue compares unfavorably to the Company's average Revenue increase of 14.19%.

Looking into fourth quarter 2018 results within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue growth. While Immune Design Corp.' s Revenue decline of -2.86% ranks overall at the positon no. 344 in the fourth quarter 2018.


IMDZ Revenue ( Y/Y Growth %) 2018
 2017 2016 2015
4th Quarter December -2.86 % -76.21 % 80.7 % -36.67 %
3rd Quarter September -11.54 % -93.67 % 76.56 % 31.36 %
2nd Quarter June 4.11 % -35.4 % -36.52 % 67.92 %
1st Quarter March -90.86 % 194.09 % -4.12 % 6366.67 %
FY   -69.54 % -45.63 % 39.43 % -

Financial Statements
Immune Design.'s fourth quarter 2018 Revenue $ 0.48 millions IMDZ's Income Statement
Immune Design.'s fourth quarter 2017 Revenue $ 0.49 millions Quarterly IMDZ's Income Statement


IMDZ Revenue (Quarter on Quarter Growth %)

 2018
 2017 2016 2015
4th Quarter December 3.48 % -5.77 % -74.91 % -75.48 %
3rd Quarter September -39.47 % -28.77 % 626.55 % 161.24 %
2nd Quarter June 52 % -86.65 % -39.25 % -8.25 %
1st Quarter March 2.04 % 165.53 % 63.16 % 7.78 %
FY (Year on Year)   -69.54 % -45.63 % 39.43 % -


Back to IMDZ Growth rate Comparisons >> Back to IMDZ Growth rate Comparisons >>


Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #84
Overall #344

Revenue Y/Y Growth Statistics
High Average Low
193.34 % 14.19 % -93.71 %
(Mar 31 2017)   (Sep 30 2017)
Revenue fourth quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #84
Overall #344
Revenue Y/Y Growth Statistics
High Average Low
193.34 % 14.19 % -93.71 %
(Mar 31 2017)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Immune Design.'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
624.27 % 65.39 % -86.66 %
(Sep 30 2016)  


IMDZ's IV. Quarter Q/Q Revenue Comment
Immune Design Corp. achieved in the IV. Quarter 2018 below company average Revenue growth of 3.48% quarter on quarter, to $ 0.48 millions.

Although the IV. Quarter 2018 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the IV. Quarter surge, eclipses the -5.77% growth in the IV. Quarter a year ago

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Immune Design.'s Revenue growth quarter on quarter, overall rank is 232.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #67
Overall #232
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #44
Healthcare Sector #67
Overall #232
Revenue Q/Q Growth Statistics
High Average Low
624.27 % 65.39 % -86.66 %
(Sep 30 2016)  


IMDZ's IV. Quarter Q/Q Revenue Comment
Immune Design Corp. achieved in the IV. Quarter 2018 below company average Revenue growth of 3.48% quarter on quarter, to $ 0.48 millions.

IV. Quarter 2018 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -5.77% in the IV. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Revenue quarter on quarter growth. While Immune Design.'s Revenue growth quarter on quarter, overall rank is 232.


Immune Design.'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Sep 30 2018)		 12 Months Ending
(Jun 30 2018)		 12 Months Ending
(Mar 31 2018)		 12 Months Ending
(Dec 31 2017)
Cumulative Revenue 12 Months Ending $ 2.20 $ 2.21 $ 2.26 $ 2.23 $ 7.20
Y / Y Revenue Growth (TTM) -69.48 % -74.85 % -86.27 % -86.76 % -45.74 %
Year on Year Revenue Growth Overall Ranking # 3787 # 0 # 767 # 1122 # 552
Seqeuential Revenue Change (TTM) -0.41 % -2.39 % 1.16 % -68.96 % -17.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 3586 # 0 # 516 # 3872 # 2019


Cumulative Revenue growth Comment
Immune Design. showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2018. If the fiscal year would end in Dec 31 2018, Immune Design.'s annual Revenue fall would be -69.48% year on year to $2 millions.

In the Healthcare sector 472 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3787.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 473
Overall # 3787

Revenue TTM Y/Y Growth Statistics
High Average Low
386.84 %
 66.25 %
-86.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 441
S&P 500 # 3586
Cumulative Revenue growth Comment
Immune Design. showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2018. If the fiscal year would end in Dec 31 2018, Immune Design.'s annual Revenue drop would be -69.48% year on year to $2 millions.

In the Healthcare sector 472 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3787.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 175
Healthcare Sector # 473
Overall # 3787

Revenue TTM Y/Y Growth Statistics
High Average Low
386.84 %
66.25 %
-86.76 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 175
Sector # 441
S&P 500 # 3586




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IMDZ's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Dec 31 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2018
Zimmer Biomet Holdings Inc -0.16%$ -0.159 millions
Tg Therapeutics Inc -0.25%$ -0.249 millions
Hanger inc.-0.31%$ -0.309 millions
Surgalign Holdings Inc -0.55%$ -0.546 millions
3m Company-0.56%$ -0.563 millions
Bio rad Laboratories Inc -0.72%$ -0.717 millions
Quest Diagnostics Inc-1.39%$ -1.394 millions
Biomarin Pharmaceutical Inc-1.42%$ -1.421 millions
Inspiremd Inc -1.44%$ -1.439 millions
Star Equity Holdings Inc -1.46%$ -1.459 millions
Prophase Labs Inc -1.47%$ -1.470 millions
Meridian Bioscience Inc -1.54%$ -1.536 millions
Sonida Senior Living Inc -1.60%$ -1.601 millions
Hca Healthcare Inc -1.78%$ -1.784 millions
Immune Design Corp.-1.86%$ -1.856 millions
Bausch Health Companies Inc -1.94%$ -1.942 millions
Opiant Pharmaceuticals Inc -2.21%$ -2.211 millions
Htg Molecular Diagnostics Inc-2.23%$ -2.227 millions
Invacare Holdings Corporation-2.31%$ -2.307 millions
Pediatrix Medical Group Inc -2.46%$ -2.458 millions
Gilead Sciences Inc -2.59%$ -2.589 millions
Dentsply Sirona Inc -2.87%$ -2.869 millions
Diversicare Healthcare Services Inc -3.26%$ -3.258 millions
Encision Inc -3.33%$ -3.326 millions
Orasure Technologies Inc-3.43%$ -3.425 millions
Alphatec Holdings Inc -3.58%$ -3.576 millions
Stereotaxis Inc -3.81%$ -3.806 millions
Sophiris Bio Inc.-3.85%$ -3.846 millions
Kaya Holdings Inc -4.21%$ -4.206 millions
Utah Medical Products Inc-4.36%$ -4.362 millions


About Immune Design. Revenue Growth Rates (IMDZ), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.